A simple high throughput micro-fluorescence in situ hybridisation technique (FISH) was used to detect chromosome 13 deletions (D13), immunoglobulin heavy chain (IgH) rearrangements, t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q23;q32), p53 loss, and numerical changes of chromosomes 3, 6, 7, 9, 10, 11 and 17 in 228 cases of multiple myeloma (MM), including 33 asymptomatic/smouldering MM (SMM). The patients were not part of a clinical trial and were from 30 different hospitals. In all, 98.4% of cases were abnormal, with 43% having IgH rearrangements and 42% D13. The low incidence of IgH rearrangements was due to a decrease in this finding with age (P ¼ 0.001) and the relatively high proportion of elderly patients in our study population (41% 470 years old). The incidence of specific IgH translocations was t(4;14) 11%, t(11;14) 16% and t(14;16) 3%. Univariate statistical testing showed D13 (P ¼ 0.002), and t(14;16) (P ¼ 0.005) to be associated with shorter survival. This effect was exaggerated for patient's aged 70 years or under but no effect on survival was seen for those over 70 years. In younger patients t(4;14) (P ¼ 0.044) and p53 deletion (Po0.001) were also significant poor prognostic indicators. Multivariate analysis showed D13 and t(14;16) to be independent prognostic variables when considered with age and clinical parameters.
Introduction
Molecular cytogenetic techniques have revolutionised our understanding of the role of chromosome abnormalities in multiple myeloma (MM) by allowing study of nondividing cells in all patients, thus avoiding problems caused by the failure of about two-thirds of diagnostic cases to yield abnormal metaphases. [1] [2] [3] Fluorescence in situ hybridisation (FISH) has shown that the extensive aneuploidy seen in most abnormal metaphases is also characteristic of nondividing cases. 4, 5 There is now a large body of evidence showing that deletion or monosomy of chromosome 13 (D13) is an indicator of poor prognosis, [6] [7] [8] [9] and increasing evidence that specific illegitimate immunoglobulin heavy chain (IgH) rearrangements also have prognostic value; t(11;14)(q13;q32) appears to be associated with a relatively good prognosis, while t(4;14)(p16;q32) and t(14;16)(q23;q32) cases seem to have a poor prognosis. [10] [11] [12] Loss of p53 at 17p13 is also associated with a poor prognosis although this appears to be a late change seen in relatively few patients. [13] [14] [15] Recently, it has been suggested from conventional cytogenetic studies that hypodiploidy is also a strong poor prognostic indicator. [16] [17] [18] Expression array analysis confirms the relevance of different chromosome abnormalities to the underlying biology of myeloma. 19, 20 Five of the numerous IgH rearrangements seen in this disease appear to be primary changes, which are intimately involved with the definition of disease subtypes; 19, 21 the t(11;14)(q13;q32) and t(6;14)(p21;q32) cause overexpression of cyclin D1 (CCND1) and cyclin D3 (CCND3), respectively, the t(4;14)(p16;q32) can dysregulate both FGFR3 and MMSET, and rearrangements of c-maf and mafB result from the t(14;16) and t (14;20) , respectively. It is not yet known whether any other IgH rearrangements can be primary changes, or whether these are all later abnormalities, presumably with less relevance to the course of the disease. Although the evidence for the importance of these chromosome abnormalities is accumulating, there are significant technical problems related to such analyses resulting from the low proportion of malignant plasma cells (PC) in the bone marrow of many patients, despite this being the primary site of disease. Although FISH can be successfully performed on whole myeloma bone marrow if there is simultaneous PC identification, the results from purified PC are easier to interpret and allow additional studies to be attempted. However, the low numbers of PC often means that the amount of material for analysis is severely limited. The number of different chromosome abnormalities implicated in the biology of myeloma means that results are more readily understood if many tests can be performed on the same samples. We have developed a simple micro-technique that allows many FISH tests to be carried out even when as few as 2 Â 10 5 PC are recovered. We report here FISH results from probes located to 12 different loci on 228 patients with MM. Our results show different patterns of chromosome abnormalities and their consequences in MM from those seen in the large published studies. 12, [22] [23] [24] We suggest that this reflects the difference between patients entered into clinical trials or seen at tertiary referral centres and those cases seen by smaller institutions, including district general hospitals.
Materials and methods

Patients
This study comprised 228 consecutive MM patients from whom samples adequate for PC purification were sent to the LRF UK Myeloma Forum Cytogenetic Database between November 2000 and July 2002. Samples were sent from 30 centres throughout the UK (see Appendix A) with informed consent for cytogenetic/FISH analysis. A total of 163 patients were studied at diagnosis while samples from the remaining 65 were taken 3-130 months after diagnosis. The diagnosis of MM (n ¼ 195) or SMM (n ¼ 33) was made according to the criteria in the myeloma management guidelines. 25 The median age was 67 years(range 27-93 years), with 41% 470 and 27% 475 years of age. Data were available on paraprotein type (223 patients), haemoglobin (Hb) (210 patients), calcium, creatinine and albumin (213 patients), b 2 M (160 patients including 104 new cases), CRP (97 patients), LDH (93 patients) and bone disease (179 patients). The missing data were accounted for by problems with retrieval or tests not performed. Sufficient data were available to stage 103 cases according to the SWOG system 26 or the international prognostic index (IPI). 25 Of these, 21% were SWOG stage I, 42% SWOG stage II, 20% SWOG stage III and 17% SWOG stage IV. The proportions for stage I, II and III of the IPI were 32, 30 and 38%, respectively. Survival data were calculated from the status of the patients in January 2005. Maximum follow-up was 50 months from the time of testing with a median of 19 months. In all, 17 patients were lost to follow-up.
Purification of PC
Bone marrow was separated over lymphoprep (Axis-Sheild PoC AS, Oslo, Norway). Wherever possible (n ¼ 156), cultures were set-up for standard cytogenetics (results to be reported elsewhere but 56 (36%) gave an abnormal karyotype consistent with a myeloma clone) before proceeding to PC purification using CD138 magnetic beads according to the manufacturer's protocol (Miltenyi Biotec Ltd., Bisley, UK). The median PC percentage achieved was 96% (range 30-100). Purified PC were harvested according to standard cytogenetic protocols and fixed in 3:1 methanol:acetic acid. Cells were lost during the harvesting procedure at variable rates, probably depending on the viability, so wherever possible 5 Â 10 5 cells were harvested to guarantee that at least 20 FISH slides could be made (see below). The suspensions were stored at À201C for at least 16 hours before being resuspended in fresh fixative for slide making. Since we found that storage of fixed cell suspension at À201C was unreliable, slides were made within a month of harvest.
Micro-FISH technique
The cell density was adjusted to approximately 2500 cell/ml by making a trial 0.2 ml spot and concentrating or diluting as necessary. 0.2 ml spots containing 100-500 cells were placed on a slide such that nine spots could fit under a 22 Â 22 mm coverslip. This cell density ensures wide separation between each of the spots and prevents crosscontamination. Eight patient samples and one control were used per slide. Controls were PC from normal bone marrow donors (n ¼ 1) or referred patients who turned out not to have a PC dyscrasia (n ¼ 5), or peripheral blood lymphocytes, either unstimulated or PHA-stimulated to give a range of cells of similar sizes to the range of malignant PC. Slides were stored at À201C until required (up to 2 years). FISH was carried out using standard protocols, and at least 100 nuclei were scored for each probe. Probes were a mixture of commercial and those grown up and labelled in the laboratory using standard techniques (see Table 1 ). A FISH result was considered abnormal if the number of affected cells was greater than the mean of the controls þ 3 standard deviations. This gave cutoff levels varying from 4% for some of the trisomies to 11% for some monosomies. The centromere and p53 probes each failed on p4 patients, the IgH probes repeatedly failed on one patient, and the results for chromosome 13 were successful for all 228 cases.
Estimation of ploidy
Only conventional cytogenetic analysis can give accurate ploidy levels but this is not possible in the majority of cases. We attempted to use our combined FISH results to estimate the ploidy of all the cases studied here. To determine how to define ploidy classes, we scored a test karyotype set for the results that would have been obtained with our FISH probe set. The test karyotypes comprised 152 abnormal MM karyotypes from our Table 2 shows the definitions for estimation of ploidy from FISH data that we derived from this exercise. Overall, 673/737 (91%) of the test set would have been assigned to the correct ploidy class using these criteria. Of the 64 cases that were not correctly classified, 43 were misclassified (hypodiploid called pseudodiploid, pseudodiploid called hypodiploid or hyperdiploid, hyperdiploid called pseudodiploid) and 21 had gain and loss of either one or two chromosomes and were considered as 'uncertain' as this class was made up of similar numbers of hypodiploid, pseudodiploid and hyperdiploid cases. This method of ploidy estimation correctly classified 55 of the 56 cases in this study for whom we had corresponding abnormal metaphases.
Statistics
Comparisons of frequencies were carried out using exact inference methods (StatXact v 5, Cytel Software Corp., Cambridge, MA, USA), Kaplan-Meier survival plots and accompanying log-rank tests using MINITAB v14 (MINITAB Inc., PA, USA) and Cox proportional hazard regressions using the specialist regression package EGRET v 2.0 (Cytel Software Corp.).
Results
Abnormality rates
Only 6/228 (2.6%) patients failed to show abnormalities with any of the probes used. The number of cases with each of the major abnormalities is shown in Table 3 . The incidence of IgH rearrangement (44%) was lower than the 55-70% expected from the literature. 12 The proximal portion of the Vysis probe used did not cover the constant region of the IgH locus and therefore it was considered possible that rearrangements due to small insertions rather than balanced translocations, reported in one cell line, 27 might have been missed. IgH tests repeated for seven slides (56 patients) using the probe set of Avet-Loiseau et al 22 to exclude this possibility gave identical results to the originals. The rearrangement was seen in the majority of cells in all but 11 of the 228 cases (5%). Four of the cases showed rearrangement of both IgH alleles and all had a t(4;14) affecting one allele. 21/228 cases (9%) showed loss of both probes for one chromosome 14, suggesting deletion or monosomy and seven cases (3%) had an extra copy of the unrearranged IgH probes, suggesting possible trisomy. a The figures in parentheses are those seen when chromosome 13 probes were considered in isolation. The higher figures are from adding the near tetraploid cases with only two copies of the 13 probes.
No problems were found with detection of the t(11;14) or t(14;16) but there was an initial underestimate of the number of t (4;14) cases. This was due to the loss of the derived chromosome 14, well-recognised with this translocation, 28, 29 coupled with apparently very proximal breakpoints on chromosome 4, such that no fusion was seen between the FGFR3 and IgH probes. Three of nine cases that had lost the der(14) from the Vysis IgH probe fell into this class, but were identified as having a t(4;14) when the Vysis t(4;14) probes were used. The remaining six cases with loss of the der(14) had previously been identified as having a t(4;14) from the initial probe combination.
Chromosome 13 deletion (D13) was seen in 90/228 cases (39%) as assessed from the presence of only one copy of either of the chromosome 13 probes. A further five near-tetraploid cases had only two copies of the 13 probes when they should have had four, so these were classed as effective D13, bringing the total to 95/228 (42%). Both Rb and D13S319 were lost in all but one case, which had lost Rb only in most cells. Bilateral loss of Rb was seen in one case and another had three copies of both probes for 13q14, suggesting possible trisomy 13.
Additional copies of the centromere probes were often seen in a smaller proportion of PC than IgH rearrangements or D13 with median involvement ranging from 46-74% compared to 90% for both other abnormalities. Hyperdiploid cases had varying combinations of centromeres with no evidence for a specific order of these gains. Losses of any of the centromere probes were rare with only five cases (2%) for chromosome 6, one for chromosome 9 (interestingly otherwise clearly hyperdiploid), and four for chromosome 17. Only 8/228 patients (3%) could not be assigned to one of the ploidy classes defined in Table 2 . These uncertain cases were excluded from further analyses involving ploidy but were retained in the total. For further analyses, the near tetraploid cases were considered to be part of the hypodiploid group in keeping with previous suggestions. 12, 16 Of the 8/246 (3%) cases with loss of one copy of p53 all but one also had D13 and 6/8 had an IgH rearrangement (3 t(4;14), 1 t(14;16), two uncharacterised). Of 30 patients with an extra copy of the 17 centromeres, only 21 (70%) had also gained a p53 signal. Conversely, three cases had an extra p53 signal without the extra 17 centromere. Table 4 lists the percentage of each of the major types of chromosome abnormality seen in association with each of the other abnormalities. Numerical abnormalities are listed both as nonhyperdiploid and as hypodiploid. Previous authors have used nonhyperdiploidy rather than hypodiploidy because of the difficulty in distinguishing between pseudodiploidy and hypodiploidy from anything other than full karyotyping 24, 30 but conventional cytogenetic studies suggest that any prognostic value depends on defining the hypodiploid class. There was a significant difference in frequency between D13 in hyperdiploid cases and either nonhyperdiploid or hypodiploid cases ( 
Associations between chromosome abnormalities
30 vs 54 or 90%, Po0.0001 for both), although the numbers of D13 cases in each group were very similar (41 hyperdiploid, 44 hypodiploid and 46 nonhyperdiploid) due to the much higher incidence of hyperdiploidy. The pattern of abnormalities with the t(11;14) was strikingly different from the other primary rearrangements, as only 8/36 (22%) t(11;14) cases had any other detectable abnormality, whereas all 32 t(4;14) and t(14;16) cases had other abnormalities and 11 of these had more than two other changes. All five near tetraploid karyotypes had an IgH rearrangement (t(11;14) n ¼ 1, t(4;14) n ¼ 1, t(14;16) n ¼ 2) as well as effective D13.
Associations between chromosome abnormalities and other features of the disease
Strong relationships between age and frequency of IgH rearrangement (Figure 1a) or frequency of hyperdiploidy ( Figure 1b) were seen, with the former decreasing with age and the latter increasing. There was no relationship between age and frequency of D13 or hypodiploidy (data not shown). There was no sign of increasing or decreasing frequency of any of the chromosome abnormalities with stage, using either the SWOG system or the IPI. There was also no association between the level of bone disease or renal failure and any of the chromosome abnormalities, although there was an association between IgH rearrangement and anemia (40% with normal Hb vs 57% with Hbo10, P ¼ 0.03). None of the individual IgH translocations, including unidentified rearrangements, had a significant association with Hb but all showed the same trend. Table 5 shows the incidence of chromosome 13 and 14 abnormalities and hyper and hypodiploidy with paraprotein type for the 223 patients for whom this information was available. The excess of t(4;14) in IgA over IgG subtypes was significant (21 vs 8%, P ¼ 0.009), as was the excess of t(14;16) in lambda over kappa subtypes (5 vs o1%, P ¼ 0.02). Hypodiploidy was overrepresented in IgA or light chain only disease compared to IgG cases (29 vs 14%, P ¼ 0.01, and 38 vs 14%, Table 4 Associations between the different cytogenetic abnormalities 
Survival analysis
The patients in this study were treated on a number of different protocols, and therefore we looked at the effect of the chromosome abnormalities on overall survival only. On univariate analysis none of the individual trisomies or deletion of IgH had any effect on survival, but D13 (P ¼ 0.002), the presence of any IgH rearrangement (P ¼ 0.046), and t(14;16) (P ¼ 0.005) were all significantly associated with a poorer survival. Hypodiploid, t(4;14) and p53 deleted patients had a shorter median survival (21, 19 and 3 months respectively, the median survival of unaffected patients being 31 months) but this was not statistically significant. We also examined nonhyperdiploidy vs hyperdiploidy but this was not significant in any analysis. The t(11;14) was the only one of the markers examined where there was any suggestion of better survival than for patients without the abnormality but this was not significant (P ¼ 0.30). When these chromosome abnormalities were combined with the clinical data for which we had adequate information (age, serum albumin, calcium, creatinine, Hb and paraprotein type) D13 (P ¼ 0.018) and t(14;16) (P ¼ 0.012) emerged as independent markers of poor prognosis, along with age (Po0.001), creatinine (Po0.001), and a paraprotein other than IgG (P ¼ 0.02). As age was such a significant prognostic indicator, we investigated its effect on the prognosis of the various chromosome abnormalities in univariate analyses. Several age cutoff limits were examined but age 70 years was considered the most rational on clinical grounds as high-dose therapy is rare above this age 31 (see Table 6 ). The cytogenetic markers showed greater discrimination in younger patients than in the full data set and much less or no discrimination in the older group (Figure 2) . The poor prognostic effect of the t(4;14) did just reach significance in the younger patients (P ¼ 0.044) and p53 deletion was highly significant (Po0.001) in this group. The prognostic effect of hypodiploidy also appeared to change in an agedependent manner but this did not reach significance until only patients under the age of 68 were considered (data not shown). Those patients with conventional cytogenetic results are included in Table 6 for comparison with the FISH results. This showed that finding an abnormal karyotype on conventional cytogenetics had a greater effect on survival than any of the individual FISH abnormalities. The equivalent values for all entries in Table 6 were also determined excluding the 33 SMM cases. The only significant differences were for patients p70 years with a t(4;14) (P ¼ 0.008 compared to 0.04 with SMM cases included), hypodiploidy (P ¼ 0.035, cf 0.091) and nonhyperdiploidy (P ¼ 0.031, cf 0.126).
Discussion
We have confirmed that nearly all cases of MM have karyotypic abnormalities by developing a technique to allow extensive testing on even small numbers of purified PC, and then using a combination of probes for specific myeloma-associated rearrangements and trisomies. This technique is now successful on 98% of samples received despite the mean PC percentage in these samples being only 6% and the median cell number 49  37  24  39  0  0  1  33  14  48  52  44  25  37  Hyper  87  66  32  52  2  67  0  0  11  38  77  65  30  44  Hypo  18  14  18  29  0  0  1  33  11  38  25  21  20  29 received 1.7 Â 10 7 . Our abnormality rate of 98.4% shows that, despite the high complexity of myeloma karyotypes, the pattern of abnormalities in nearly all cases involves at least one of IgH rearrangement, D13 or trisomy for a select group of chromosomes.
At the start of this project, we had not appreciated the potential need to distinguish between hypodiploid and other aneuploid karyotypes as a survival indicator and therefore the centromere probes were chosen only with a view to detecting the classic pattern of trisomies vs other cases. By careful comparison with the most fully characterised myeloma karyotypes from our own and published cases, we evolved a formula to convert number of FISH signals into a ploidy level. While this gave generally accurate results, the absence of any frequent marker of chromosome loss other than chromosome 13 meant that a small proportion of cases were incorrectly classified, and that the association between hypodiploidy and D13 was probably overestimated. All but one of the 56 cases with corresponding conventional cytogenetic results were correctly classified by the formula. The exception was hypodiploid with a t(11;14) but no D13; comparison with the test karyotype set suggests that cases like this were the biggest single group that would have been misclassified. We estimate that 11 such cases (4% of total cases) were called near diploid when they were really hypodiploid. We are currently investigating whether a different, relatively small set of centromere probes can be used which will give a more accurate guide to ploidy when only FISH is available.
In this series the frequency of D13, at 42%, was within the expected range. 12 We found a lower rate in SMM (30%) and a higher rate (57%) in the seven MM cases known to have evolved from MGUS. These results are consistent with the theory that this abnormality could contribute to the evolution of MGUS to MM. 32 Against this idea were the results from a single patient with smouldering myeloma who has had a low level of D13 (o20%) detected on three occasions in 4 years with no evidence of an increase in the size of the D13 clone or of disease progression. Thus the acquisition of D13 in MGUS or SMM cannot be a universal indicator of imminent disease progression. Chromosome abnormalities in myeloma FM Ross et al
The overall frequency of IgH rearrangement found in this series was much lower than that described in other FISH series. It is thought that some IgH rearrangements are secondary changes, 21 but the proportion of such cases has not been quantified in any large series. Although there is some disparity in the reported incidence of IgH translocations between MGUS and MM cases, the difference is usually small (eg nearly 50% in MGUS compared with 55-70% in MM), 12 suggesting either that relatively few of the IgH rearrangements are secondary changes or that even the secondary translocations usually arise before overt MM is diagnosed. Thus differences in the proportion of late stage MM cases are unlikely to cause a major difference in incidence of IgH rearrangements seen. This is consistent with finding that only 12 of our 107 cases with an IgH rearrangement (11%) had direct evidence for being secondary rearrangements by having another abnormality in a substantially higher proportion of cells. An explanation for the low overall IgH translocation rate emerged when we showed that there was a strong inverse relationship between incidence of IgH rearrangement and age. This age effect has not previously been reported but it can be inferred from the inverse relationship between IgH rearrangement and hyperdiploidy noted by Fonseca et al 22 and the same group's separate finding of increasing hyperdiploidy with age. 24 We believe that our series of unselected patients, with 27% of the study population older than 75, has many more elderly cases than other large published series, which are essentially from large multicentre trials or single institutions with high tertiary referral rates that may be biased towards younger patients.
The prevalence of the specific IgH rearrangements implicated as primary changes varies in different series but overall approximately 15% of cases have a t(11;14), 15% t(4;14) and 6% t(14;16). 12 Although our series showed the expected 16% (36/228) rate of t(11;14,) the rate was only 11% (25/228) for t(4;14) and 3% (7/228) for t (14;16) . Both the t(4;14) and t (14;16) translocations are associated with more aggressive disease features, 10, 23 therefore it is possible that trial and tertiary referral centre patients show an overrepresentation of this group. This hypothesis is consistent with our own finding of a significantly higher rate of the t(4;14) in the first 200 patients entered into the MRC Myeloma IX trial (data not shown). It is interesting that the generally less aggressive t (11;14) was seen at the expected frequency in our series of patients despite the older age-group.
We have confirmed the strong association between t(4;14) or t(14;16) and D13, the association of all three of these changes and hypodiploidy, and the relative infrequency of D13 with t (11;14) . 22, 31 Despite these associations, all of the translocations were also seen in hyperdiploid cases. It is not yet clear whether these three translocations only occur as primary rearrangements in MM, although there is limited evidence that the t (11;14) at least can be a secondary change. 21 We do not yet understand the reason for the association between the primary IgH rearrangements and nonhyperdiploidy; it may be that hyperdiploid cases with one of these abnormalities are different from the hypodiploid cases, possibly as a result of the order in which the chromosome abnormalities arise. Larger numbers of cases will be needed to address this question. There was a striking absence of any other abnormalities with t(11;14), a pattern not seen for any other IgH rearrangement. Comparison with conventional karyotypes confirms the relative simplicity of most t (11;14) karyotypes and the low frequency of any of the common trisomies. Our rate of D13 with t (11;14) was particularly low at only 20% of t (11;14) cases rather than the 40-49% reported by others [22] [23] [24] and 35% found in metaphase analysis (our results þ search of complete Mitelman database). If D13 is a marker of aggressive or later stage disease, this might indicate that our series has a smaller proportion of such patients compared to other studies. The low frequency of p53 deletion in our series also tends to support this suggestion.
All recent publications looking at chromosome abnormalities in MM show that these can have significant prognostic effects. Our results are in agreement with the literature for some abnormalities but not others. D13 was clearly associated with a poor prognosis in our series and this was sufficiently strong to be an independent marker when considered with the available clinical parameters. However, Smadja et al 16 proposed that the effect of D13 in conventional cytogenetic studies could be entirely explained by its strong association with hypodiploidy, although Fassas et al 3 have shown that in their large series both D13 and hypodiploidy are independent markers of an extremely poor prognosis. In our FISH study, hypodiploidy showed a trend towards poorer survival but was not significant, even in younger patients, confirming its lesser effect than D13. It is not clear whether this result is due to the inaccuracies in detecting hypodiploidy by this FISH method, or whether hypodiploidy is genuinely less relevant to survival than D13 in the absence of the factors allowing myeloma cells to divide in vitro.
Our results for the t(4;14) and t(14;16) differed from other studies. The latter showed a much stronger poor prognostic effect than has been reported 10, 23 but was based on only seven patients, six of whom died within a year. Thus this may simply be the exaggerated effect of a small cohort. The poor prognostic effect of the t(4;14) was not strong enough to be significant in the whole patient group, although it did reach significance in the younger patients, and this was considerably increased by the exclusion of SMM patients. There are a number of possible explanations for the apparent lesser effect of t(4;14) in our series. It may simply be due to the fluctuations possible in a small sample. It may be that the context of the t(4;14) is crucial; our series had a relatively high proportion of cases (6/25, 24%) with hyperdiploid rather than hypodiploid karyotypes. It may also be that the precise breakpoint on chromosome 4 is important for prognosis, possibly by changing the genes affected by the translocation. It is not clear whether all other series would have detected cases with loss of the der(14) and a proximal 4p breakpoint and therefore different series may be examining different parameters.
A single previous suggestion that trisomies for chromosomes 6, 9 or 17 had a particularly good outcome 5 could not be substantiated, nor could we find a poor prognosis associated with monosomy 14. 17 This abnormality, however, was extrapolated from loss of 14q32 probes, which may have been interstitial deletions rather than monosomy.
Analysing survival results by age showed that the significant effect of chromosome abnormalities was confined to those aged 70 years or under. The absence of prognostic effect in older patients was not due to better survival of the patients with the abnormalities, but to such a poor overall survival of this group that the chromosome changes had little effect. It is not clear whether this is a result of the natural history of the disease or to the effectiveness of high-dose therapy in the younger patients. Much larger numbers of patients with details of treatment will be needed to answer this question.
Our series is unusual in including patients with SMM in the survival analysis. The only significant change seen when these patients were excluded was that the significance of the adverse effect of t(4;14) in younger patients was stronger, and both hypodiploidy and nonhyperdiploidy also emerged as significant poor prognostic indicators in the younger age group. All these factors were still substantially less significant than D13 or p53 loss. The greater effect when SMM cases are excluded implies that the presence of these abnormalities alone is not enough to determine the prognosis and therefore clinicians should not be tempted to treat apparently stable disease simply because a t(4;14) is present. It is well recognised that the D13 has a much greater poor prognostic effect if abnormal metaphases can be obtained than if it is only detectable by FISH and Shaughnessy et al 18 have suggested that the additional factor causing this effect is stromal cell independence. Analogous factors may also influence the prognostic effects of t(4;14) and ploidy.
Although the emphasis in this report is on our FISH results, the corresponding full cytogenetic results available for 151 patients with follow-up confirmed that the ability of malignant PC to divide in vitro is an extremely strong indicator of poor prognosis. 18 
Conclusions
The ability to examine many different FISH probes in a large series of myelomas has confirmed the strong association between the primary IgH rearrangements and nonhyperdiploid karyotypes, with the t(4;14) and t(14;16) also being preferentially associated with D13 and hypodiploidy. The incidence of IgH rearrangements, and in particular t(4;14) and t(14;16), were lower than previously published but this was shown to be due to the combination of a low incidence in elderly patients and a high proportion of such patients in this series of patients who were not the subjects in a clinical trial. This is more likely to reflect the normal range of unselected myeloma patients. Age was also shown to have a profound effect on the prognosis associated with chromosome abnormalities, with the significant effects of D13, t(14;16) or abnormal karyotypes on conventional cytogenetic analysis all being enhanced in patients of a suitable age for high-dose therapy but diminished or abolished in those over the age of 70 years, and the effects of t(4;14) and p53 only reaching significance in the younger cohort. D13 was confirmed as being a useful independent marker of poor prognosis and appeared to have a much stronger effect than hypodiploidy as determined by FISH.
